Roche Diagnostics Canada launches Accu-Chek®Mobile, the world’s first strip-free blood glucose monitoring device
The state-of-the-art Accu-Chek® Mobile system makes handling used lancets and test strips a thing of the past
Montréal, March 9, 2011 – Roche Diagnostics Canada, a trailblazer in the healthcare field, is proud to introduce Accu-Chek® Mobile, the first strip-free blood glucose monitoring device available on the market. The state-of-the-art Accu-Chek® Mobile system eliminates the need to handle used lancets and test strips. Specially developed for people living with diabetes, the device yields accurate, reliable blood glucose readings within five seconds, making it a particularly practical solution for users of rapid-acting insulin.
For the 3 million Canadians with diabetes, and especially the 10% who have type 1 diabetes (complete insulin deficiency), the new Accu-Chek® Mobile glucose monitoring device provides, at long last, a quick, simple way of checking blood glucose levels. Lightweight and portable, the device features a unique test cassette pre-loaded with a continuous testing tape and a lancet drum. It also boasts a simplified three-step testing process, compared with the average 11 steps required with single strip devices. Accu-Chek® Mobile allows users to perform up to 50 tests before replacing the cassette. The fast, convenient device provides readings within five seconds, with only a minimal blood sample, thanks to the improved Accu-Chek FastClix lancet system.
Accu-Chek® Mobile can also store up to 500 readings as well as averages over 7, 14 and 30 days, enabling users to consult their testing history and thus allow them to better manage their blood glucose levels over time. Moreover, data from the device can be uploaded to Excel or Accu-Chek® software for tracking purposes.
Roche’s Accu-Chek® Mobile blood glucose monitoring device is now available in drug stores at the suggested retail price of $75.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are legally protected.
– 30 –
For further information, please contact:
Katia Robillard, Optimum
Michèle Beaubien, Roche Diagnostics Canada